Download PDF

1. Company Snapshot

1.a. Company Description

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis.Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology.


The company was incorporated in 2015 and is based in South San Francisco, California.

Show Full description

1.b. Last Insights on KZR

Kezar Life Sciences' recent performance has been positively influenced by a regulatory update on its Zetomipzomib program in autoimmune hepatitis. The company has initiated a strategic review process to explore alternatives that maximize shareholder value, with TD Cowen supporting the process. Additionally, the company received a rating upgrade to Buy from Zacks, citing growing optimism about its earnings prospects. These developments have contributed to a favorable outlook, with the company's novel small molecule therapeutics addressing unmet needs in immune-mediated diseases.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Reviewing Dyadic International (NASDAQ:DYAI) and Kezar Life Sciences (NASDAQ:KZR)

Dec -03

Source: defenseworld.net

Card image cap

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

Nov -12

Source: businesswire.com

Card image cap

Brokerages Set Kezar Life Sciences, Inc. (NASDAQ:KZR) Target Price at $9.00

Oct -20

Source: defenseworld.net

Card image cap

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

Oct -16

Source: businesswire.com

Card image cap

All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy

Sep -17

Source: zacks.com

Card image cap

Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)

Mar -25

Source: seekingalpha.com

Card image cap

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

Mar -24

Source: businesswire.com

Card image cap

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

Nov -05

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.93%)

6. Segments

Immune-mediated Diseases and Cancer Therapeutics

Expected Growth: 10.93%

Kezar Life Sciences' Immune-mediated Diseases and Cancer Therapeutics segment growth is driven by increasing demand for novel therapies, advancements in immunology research, and a growing pipeline of promising candidates. The company's focus on modulating protein degradation pathways and targeting immune cells also contributes to its growth, as these approaches have shown potential in treating various immune-mediated diseases and cancers.

7. Detailed Products

Zerviatinib

Zerviatinib is an oral, selective inhibitor of the tyrosine kinase ZAK, which is a key regulator of the NLRP3 inflammasome. It is being developed as a potential treatment for severe and debilitating autoimmune diseases.

KZR-616

KZR-616 is a selective inhibitor of the immunoproteasome, which is a key regulator of immune cell activation. It is being developed as a potential treatment for severe autoimmune diseases.

8. Kezar Life Sciences, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Kezar Life Sciences, Inc. is moderate due to the presence of alternative treatments and therapies for cancer and autoimmune diseases.

Bargaining Power Of Customers

The bargaining power of customers for Kezar Life Sciences, Inc. is low due to the company's focus on rare and orphan diseases, which limits the negotiating power of patients and healthcare providers.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Kezar Life Sciences, Inc. is moderate due to the company's reliance on a limited number of suppliers for raw materials and services.

Threat Of New Entrants

The threat of new entrants for Kezar Life Sciences, Inc. is high due to the growing interest in biotechnology and pharmaceutical research, which attracts new companies and investors to the industry.

Intensity Of Rivalry

The intensity of rivalry for Kezar Life Sciences, Inc. is high due to the competitive landscape of the biotechnology and pharmaceutical industries, where companies compete for market share and intellectual property.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 6.52%
Debt Cost 6.31%
Equity Weight 93.48%
Equity Cost 6.31%
WACC 6.31%
Leverage 6.97%

11. Quality Control: Kezar Life Sciences, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
OncoCyte

A-Score: 3.7/10

Value: 7.0

Growth: 6.0

Quality: 3.2

Yield: 0.0

Momentum: 4.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Kezar Life Sciences

A-Score: 3.5/10

Value: 8.0

Growth: 5.4

Quality: 6.0

Yield: 0.0

Momentum: 0.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Allogene Therapeutics

A-Score: 3.3/10

Value: 7.8

Growth: 4.3

Quality: 6.1

Yield: 0.0

Momentum: 0.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Biomea Fusion

A-Score: 3.2/10

Value: 6.8

Growth: 3.3

Quality: 3.6

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Pliant Therapeutics

A-Score: 2.6/10

Value: 7.8

Growth: 3.2

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Maravai LifeSciences

A-Score: 2.2/10

Value: 7.2

Growth: 2.1

Quality: 3.2

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

6.24$

Current Price

6.24$

Potential

-0.00%

Expected Cash-Flows